-
Zhejiang Gongdong to Acquire Trademark Plastics for Overseas Expansion
•
China-based Zhejiang Gongdong Medical Technology Co., Ltd is set to acquire core assets of US firm Trademark Plastics, Inc. for USD 42 million. This strategic move aims to enhance the company’s overseas manufacturing capabilities and achieve synergies through complementary product portfolios. Acquisition DetailsFounded in 1989, Trademark Plastics, Inc. (TPI) specializes…
-
Shanghai Weimu Medical Raises Pre-Series A+ Funding for Clinical Development
•
China-based high-end interventional device maker Shanghai Weimu Medical Technology Co., Ltd has reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing round. The round was led by Woyong Fund. The proceeds will be used to accelerate the clinical development of core pipelines, marking a significant step in…
-
MicroPort Endovascular Plans RMB 2.55 Billion Private Placement
•
China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) plans to raise up to RMB 2.55 billion (USD 378 million) via a private placement. The proceeds will be used to fund several strategic initiatives, including the development of its global headquarters and innovation and industrialization plan projects, research into peripheral…
-
NeuShen Therapeutics Partners with UMass Chan for ALS Gene Therapy Development
•
Sino-US biotech firm NeuShen Therapeutics Inc., focused on central nervous system (CNS) disorders, has announced a three-year Sponsored Research Agreement with UMass Chan Medical School (UMass Chan) to develop gene therapy for amyotrophic lateral sclerosis (ALS), a rare and severe neurological disease. The collaboration aims to advance therapeutic solutions for…
-
Pfizer Reports Record Revenues as COVID-19 Sales Soar; 2023 Guidance Amid Market Shifts
•
US-based Pfizer Inc. (NYSE: PFE) reported its Q4 2022 financial results, highlighting an all-time high in 12-month revenues of USD 100.3 billion, up 30% year-on-year (YOY) excluding foreign exchange impacts. The company’s COVID-19 portfolio, including the Comirnaty vaccine and Paxlovid treatment, drove significant growth, though Pfizer expects a substantial revenue…
-
Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development
•
South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals (CSP) for its first-in-class PRS inhibitor, bersiporocin. Under the agreement, CSP will hold exclusive development and commercial rights to the drug in Greater China, including mainland China, Hong Kong, Taiwan, and Macau. The deal covers…
-
Enkang Pharma Secures Series B Funding for DRIPs-Targeted Cancer Therapy
•
Enkang Pharmaceutical Technology (Guangzhou) Co., Ltd, a developer of DNA replication-initiation proteins (DRIPs)-targeted drugs, has reportedly raised “tens of millions” of renminbi in a Series B financing round. The round was solely led by CHER AMI Investment, with proceeds earmarked for new drug research and development. EN002 Gel: First-in-Class Cancer…
-
Tianjin-Based Protein T Raises RMB 100 Million in Series A Financing
•
Tianjin-based biotech Protein T, focused on multi-omics research, has reportedly raised close to RMB 100 million (USD 14.7 million) in a Series A financing round. The sole investor was Shanghai Dinghui Baifu Wealth Management. The proceeds will be used to facilitate Protein T’s business expansion, strategic layout, and the translation…
-
Dartsbio Pharmaceuticals Secures RMB 100 Million in Series B Financing
•
Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has reportedly raised over RMB 100 million in a Series B financing round. The round was led by Yuecai Holdings’ biomedicine fund, with participation from Fuho Capital, Qianhai Liyuan Fund Management, Ningbo Jingxing Zhiyuan Venture Capital, and Ningbo Jinghang Intelligent Inspection Venture Capital Fund.…
-
Ascentage Pharma Raises HKD 550 Million in Secondary Offering for Pipeline Expansion
•
Suzhou-based Ascentage Pharma (HKG: 6855) is set to conduct a secondary offering of 22.5 million new shares to prominent investors, including JPMorgan Chase & Co., China International Capital Co., Ltd, and Citigroup Global Markets Asia Ltd. The offering is priced at HKD 24.45 (USD 3.12) per share, raising a total…
-
MDHC Group Raises Hundreds of Millions in Third Financing Round
•
Jiangsu-based MDHC Life Technologies (Kunshan) Co.,Ltd, a leading platform in minimally invasive surgery and life sciences consumables known as “Big Smart Manufacturing,” has reportedly raised hundreds of millions of RMB in its third financing round. The round was led by Luxin Venture Capital, with contributions from Ruicheng Private Equity Fund…
-
Bliss Bio Raises RMB 100 Million in Series B+ Financing for Oncology Pipeline
•
Hangzhou-based oncology-focused clinical-stage biotech Bliss Bio has reportedly raised over RMB 100 million (USD 14.7 million) in a Series B+ financing round. The round was led by In Capital, with contributions from Oriental Fortune Capital and Sherpa Healthcare Partners. The proceeds will be used to advance clinical studies for BB-1701,…
-
Suzhou Powersite Electric Secures Series B Funding for X-ray Imaging Expansion
•
China-based X-ray imaging core component supplier Suzhou Powersite Electric Co., Ltd has reportedly raised hundreds of millions of renminbi in a Series B financing round. The round was led by Yuanbio Venture Capital, with contributions from Suzhou High-Tech Venture Capital, Medpark, Northern Light Venture Capital, Cross Currents Capital, and SND…
-
Beijing Interbio Secures Pre-Series A Funding for SPR Technology Expansion
•
Beijing Interbio Biology & Technology Co., Ltd, a China-based company specializing in surface plasmon resonance (SPR) technology and other life sciences testing instruments, has reportedly raised an undisclosed amount in a Pre-Series A financing round led by Jintan Capital. The proceeds will be used to support commercial equipment installation, mass…
-
Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines
•
Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly raised “tens of millions” of US dollars in a Series A1 financing round. The funding was led by Great Eagle VC, with participation from Baidu Venture, Sincere Capital, GDHT Capital, SPARK VC, and existing investor…
-
ConceMed Raises Pre-Series A Funding to Expand Digestive Endoscope Pipeline
•
ConceMed, a Guangdong-based maker of digestive soft electronic endoscopes, has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The funding was led by Cowin Capital, with participation from the National Innovation Center for Advanced Medical Devices. The proceeds will be used to accelerate the company’s…
-
ReLive Biotechnologies Acquires Co.Don AG, Secures USD 36 Million for Expansion
•
Tissue engineering and regenerative medicine start-up ReLive Biotechnologies Ltd has announced the full acquisition of Germany-listed Co.Don AG (FRA: CNW), gaining rights to its cartilage repair cell therapy Spherox/Chondrosphere. The move comes as the Hong Kong-based company secured over USD 36 million in a Series A financing round led by…
-
JHM Biopharma Raises RMB100 Million to Expand Protein Drug Pipeline
•
Hangzhou-based protein drug developer JHM Biopharma has reportedly secured close to RMB100 million (USD14.9 million) in a Series A+ financing round. The funding was led by 3E Bioventures and Guangdian Capital. Proceeds from the round will be allocated towards the development and expansion of JHM Biopharma’s product pipeline, as well…
-
LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion
•
Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round. The funding was led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management, with additional participation from HLC, Bayland Capital, HM Capital, Cas Holding, and TDF…
